NEW YORK (GenomeWeb) – In fiscal year 2018, Myriad Genetics is anticipating reduced revenues from its hereditary cancer testing business, but it is also hoping to offset those declines with sales of its new products and cost-reduction initiatives.
Myriad Projects Flat FY2018 Revenues; Expects New Tests to Offset Lower Hereditary Cancer Sales
Premium
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.